Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma

Ferretti, Valeria Alejandra; León, Ignacio E.

doi:10.1007/s11864-021-00839-y

Cited by 14 publications

(9 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous studies have indicated that many lncRNAs are dysregulated in cancers (Iyer et al, 2015;Yan et al, 2015). Aberrant expression of lncRNAs is associated with tumor growth (Zhou et al, 2020), metastasis (Liao et al, 2021), angiogenesis (Jin et al, 2020), chemotherapy resistance (Ferretti and León, 2021), and metabolism (Xu et al, 2021). Therefore, lncRNAs are regarded as important regulators of the pathological processes in cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications

Wang

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA) DANCR (also known as ANCR)—differentiation antagonizing non-protein coding RNA, was first reported in 2012 to suppress differentiation of epithelial cells. Emerging evidence demonstrates that DANCR is a cancer-associated lncRNA abnormally expressed in many cancers (e.g., lung cancer, gastric cancer, breast cancer, hepatocellular carcinoma). Increasing studies suggest that the dysregulation of DANCR plays critical roles in cancer cell proliferation, apoptosis, migration, invasion, and chemoresistance in vitro and tumor growth and metastasis in vivo. Mechanistic analyses show that DANCR can serve as miRNA sponges, stabilize mRNAs, and interact with proteins. Recent research reveals that DANCR can be detected in many body fluids such as serum, plasma, and exosomes, providing a quick and convenient method for cancer monitor. Thus DANCR can be used as a promising diagnostic and prognostic biomarker and therapeutic target for various types of cancer. This review focuses on the role and mechanism of DANCR in cancer progression with an emphasis on the clinical significance of DANCR in human cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications

Wang

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that ANRIL expression is upregulated in osteosarcoma tissues by comparison to adjacent normal tissues and may play a role in the regulation of cell proliferation, growth, and metastasis of osteosarcoma and other cancer types [ 30 , 31 , 32 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ]. In relation to chemotherapeutic response, ANRIL has also been reported to promote cell chemoresistance, in multiple cancer types, to various therapeutic agents including cisplatin [ 33 , 34 , 35 , 36 , 37 , 52 , 53 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

“…The lncRNA ANRIL (also known as CDKN2B-AS1 ) was first identified from familial melanoma patients with a large germline deletion in the INK4B-ARF-INK4A gene cluster, and has been previously characterized as an oncogene in osteosarcoma and other cancer types [ 20 , 27 , 28 , 29 , 30 ]. In relation to chemotherapeutic response, previous studies have shown ANRIL to promote cell chemoresistance in multiple cancers; however, the impact of ANRIL in response to cisplatin and doxorubicin in the treatment of osteosarcoma is not fully elucidated [ 20 , 31 , 32 , 33 , 34 , 35 , 36 , 37 ].…”

Section: Introductionmentioning

confidence: 99%

Long Non-Coding RNA ANRIL as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma

Lee

Ferdjallah

Moore

et al. 2021

IJMS

View full text Add to dashboard Cite

Osteosarcoma has a poor prognosis due to chemo-resistance and/or metastases. Increasing evidence shows that long non-coding RNAs (lncRNAs) can play an important role in drug sensitivity and cancer metastasis. Using osteosarcoma cell lines, we identified a positive correlation between the expression of a lncRNA and ANRIL, and resistance to two of the three standard-of-care agents for treating osteosarcoma—cisplatin and doxorubicin. To confirm the potential role of ANRIL in chemosensitivity, we independently inhibited and over-expressed ANRIL in osteosarcoma cell lines followed by treatment with either cisplatin or doxorubicin. Knocking-down ANRIL in SAOS2 resulted in a significant increase in cellular sensitivity to both cisplatin and doxorubicin, while the over-expression of ANRIL in both HOS and U2OS cells led to an increased resistance to both agents. To investigate the clinical significance of ANRIL in osteosarcoma, we assessed ANRIL expression in relation to clinical phenotypes using the osteosarcoma data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset. Higher ANRIL expression was significantly associated with increased rates of metastases at diagnosis and death and was a significant predictor of reduced overall survival rate. Collectively, our results suggest that the lncRNA ANRIL can be a chemosensitivity and prognosis biomarker in osteosarcoma. Furthermore, reducing ANRIL expression may be a therapeutic strategy to overcome current standard-of-care treatment resistance.

show abstract

“…Emerging evidence has dissected that ncRNAs participate in OS tumorigenesis and progression ( Ghafouri-Fard et al, 2021 ). For example, ncRNAs are involved in chemotherapeutic drug resistance in osteosarcoma ( Ferretti and Leon, 2021 ; Lin et al, 2021 ). In recent years, ncRNAs were reported to critically participate in CSCs in a variety of cancers, including OS ( Lei et al, 2020 ; Humphries et al, 2021 ; Melendez-Zajgla and Maldonado, 2021 ).…”

Section: Noncoding Rnas In Osmentioning

confidence: 99%

The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets

Liu

Shang

2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Osteosarcoma (OS) is the common bone tumor in children and adolescents. Because of chemotherapy resistance, the OS patients have a poor prognosis. The one reason of chemotherapeutic resistance is the development of cancer stem cells (CSCs). CSCs represent a small portion of tumor cells with the capacity of self-renewal and multipotency, which are associated with tumor initiation, metastasis, recurrence and drug resistance. Recently, noncoding RNAs (ncRNAs) have been reported to critically regulate CSCs. Therefore, in this review article, we described the role of ncRNAs, especially miRNAs, lncRNAs and circRNAs, in regulating CSCs development and potential mechanisms. Specifically, we discussed the role of multiple miRNAs in targeting CSCs, including miR-26a, miR-29b, miR-34a, miR-133a, miR-143, miR-335, miR-382, miR-499a, miR-1247, and let-7days. Moreover, we highlighted the functions of lncRNAs in regulating CSCs in OS, such as B4GALT1-AS1, DANCR, DLX6-AS1, FER1L4, HIF2PUT, LINK-A, MALAT1, SOX2-OT, and THOR. Due to the critical roles of ncRNAs in regulation of OS CSCs, targeting ncRNAs might be a novel strategy for eliminating CSCs for OS therapy.

show abstract

Long Non-coding RNAs in Cisplatin Resistance in Osteosarcoma

Cited by 14 publications

References 112 publications

Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications

Long Non-coding RNA DANCR in Cancer: Roles, Mechanisms, and Implications

Long Non-Coding RNA ANRIL as a Potential Biomarker of Chemosensitivity and Clinical Outcomes in Osteosarcoma

The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets

Contact Info

Product

Resources

About